Insmed, Inc. (NASDAQ:INSM) Shares Purchased by Brown Advisory Inc.

Brown Advisory Inc. boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 1.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 672,450 shares of the biopharmaceutical company's stock after buying an additional 9,453 shares during the quarter. Brown Advisory Inc. owned approximately 0.37% of Insmed worth $51,301,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. lifted its holdings in Insmed by 26.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 325,307 shares of the biopharmaceutical company's stock valued at $24,818,000 after buying an additional 68,949 shares in the last quarter. GF Fund Management CO. LTD. lifted its position in shares of Insmed by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 4,581 shares of the biopharmaceutical company's stock worth $349,000 after purchasing an additional 825 shares during the period. OneDigital Investment Advisors LLC lifted its position in shares of Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock worth $399,000 after purchasing an additional 1,673 shares during the period. Moody Aldrich Partners LLC lifted its position in shares of Insmed by 150.9% in the 1st quarter. Moody Aldrich Partners LLC now owns 89,020 shares of the biopharmaceutical company's stock worth $6,791,000 after purchasing an additional 53,542 shares during the period. Finally, KBC Group NV lifted its position in shares of Insmed by 9.9% in the 1st quarter. KBC Group NV now owns 7,551 shares of the biopharmaceutical company's stock worth $576,000 after purchasing an additional 678 shares during the period.

Insmed Stock Performance

NASDAQ:INSM traded up $1.52 during trading hours on Friday, hitting $98.18. 3,244,487 shares of the company were exchanged, compared to its average volume of 2,282,446. The stock has a market capitalization of $18.63 billion, a price-to-earnings ratio of -16.50 and a beta of 0.90. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $106.83. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. The company's 50 day moving average price is $83.40 and its 200-day moving average price is $77.39.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The firm's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.06) EPS. As a group, research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Michael Alexander Smith sold 1,879 shares of the company's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $73.50, for a total value of $138,106.50. Following the sale, the insider directly owned 67,718 shares of the company's stock, valued at $4,977,273. This represents a 2.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the sale, the insider directly owned 89,407 shares in the company, valued at $8,352,401.94. This trade represents a 52.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 546,516 shares of company stock worth $48,737,083. Company insiders own 3.00% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on INSM. JPMorgan Chase & Co. increased their target price on Insmed from $90.00 to $111.00 and gave the company an "overweight" rating in a research report on Tuesday. Citigroup raised Insmed to a "buy" rating in a research report on Tuesday, June 10th. Morgan Stanley increased their target price on Insmed from $90.00 to $102.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. Wells Fargo & Company increased their target price on Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. Finally, The Goldman Sachs Group boosted their price objective on shares of Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $108.07.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.